Back to Search
Start Over
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment--California, December 2021-May 2022
- Source :
- Morbidity and Mortality Weekly Report. June 24, 2022, Vol. 71 Issue 25, p830, 4 p.
- Publication Year :
- 2022
-
Abstract
- On June 21, 2022, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). Nirmatrelvir/ritonavir (Paxlovid) is a combination protease inhibitor that blocks replication of SARS-CoV-2 [...]
- Subjects :
- Pfizer Inc.
United States. Food and Drug Administration
Paxlovid (Medication) -- Health aspects
Development and progression
Health aspects
Hospital emergency services -- Health aspects
Disease susceptibility -- Development and progression
Protease inhibitors -- Health aspects
Pharmaceutical industry -- Health aspects
COVID-19 -- Development and progression
Hospitals -- Emergency service
Subjects
Details
- Language :
- English
- ISSN :
- 01492195
- Volume :
- 71
- Issue :
- 25
- Database :
- Gale General OneFile
- Journal :
- Morbidity and Mortality Weekly Report
- Publication Type :
- News
- Accession number :
- edsgcl.709814109